FDA grants priority review to Tevimbra combo in HER2+ GEA
CURRENT BRIEF VERSION: BeOne Medicines said the FDA has accepted for Priority Review a supplemental biologics license application for tislelizumab, marketed as Tevimbra, in combination with zanidatamab-hrii and chemotherapy as a first-line treatment for adults with unresectable locally advanced or metastatic HER2-positive gastric, gastroesophageal junction, or esophageal adenocarcinoma. BeOne also said it plans to participate in the FDA’s Project Orbis program. The filing is based on the phase 3 HERIZON-GEA-01 trial, which enrolled 914 adults and compared zanidatamab plus chemotherapy, with or without tislelizumab, against trastuzumab plus chemotherapy. In the tislelizumab-containing arm, median overall survival reached 26.4 months versus 19.2 months in the trastuzumab control arm; median progression-free survival was 12.4 months versus 8.1 months, and benefit was reported regardless of PD-L1 status. The zanidatamab-plus-chemotherapy arm also showed prolonged progression-free survival, with median overall survival of 24.4 months. Results were presented at the 2026 ASCO GI Cancers Symposium and cited in company materials. The FDA has set a target action date in the third quarter of 2026 under Priority Review. (nasdaq.com)
Why it matters: While this is a human oncology development rather than a veterinary one, it’s notable for clinicians and industry watchers because it reflects the continued expansion of biomarker-driven combination therapy, including checkpoint inhibition plus HER2-targeted treatment. The added detail that benefit was seen regardless of PD-L1 status is especially notable in a space where PD-L1 can shape treatment positioning. That broader trend can influence comparative oncology research, partnership activity, and expectations around how regulators evaluate multi-agent regimens tied to strong survival data. It also underscores how quickly first-line standards can shift when a late-stage study shows a meaningful overall survival gain over trastuzumab-based therapy. (fda.gov)
What to watch: Watch for the FDA’s decision in Q3 2026, whether Project Orbis leads to aligned reviews in other countries, any label details if approved, and publication of the full HERIZON-GEA-01 dataset in a peer-reviewed journal. (nasdaq.com)